Evolva SA (SIX: EVE) (Basel, Switzerland) was founded in 2004 around a proprietary technology platform that uses synthetic biology to create innovative small molecule drugs and other high value compounds.

Evolva has used this platform across a range of applications and have created novel products and a pipeline of strongly differentiated compounds that address major commercial needs.

The most important compounds are: Resveratrol, Vanilla, Pomecin, Stevia and Saffron.

Sunstone has sold all shares and is no longer a shareholder of the company.


For more information, please contact:

Søren Lemonius, Msc

Managing General Partner

Phone: +45 4081 4889